Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | MC5R | P33032 | 1/20 | 0.68 |
| ▸ | MC3R | P41968 | 1/20 | 0.68 |
| ▸ | MC1R | Q01726 | 1/20 | 0.68 |
| ▸ | G6PD | P11413 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | MPO | P05164 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | HTR1D | P28221 | 1/20 | 0.61 |
| ▸ | HTR1B | P28222 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | HTR7 | P34969 | 1/20 | 0.61 |
| ▸ | CTSK | P43235 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25246907 | 0.98 | HTR2A (0.68) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL17232881 | 0.85 | MC5R (0.83) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL7970552 | 0.84 | MC5R (0.81) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL4985934 | 0.82 | HTR2A (0.77) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL379409 | 0.82 | HTR2A (1.00) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL3377723 | 0.82 | HTR2A (0.70) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL10923944 | 0.82 | HTR2A (0.70) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL4428860 | 0.82 | HTR2A (0.70) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL10089577 | 0.82 | HTR2A (0.70) | HTR2AKDM4EALDH1A1HTR1AHTT | |
| SCHEMBL106450 | 0.82 | HTR2A (0.70) | HTR2AKDM4EALDH1A1HTR1AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1314728-A1 | Pyridyl and pyrimidinyl imines as intermediates for imidazole derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-28 | — | — | EP | claimed |
| EP-0831830-B1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | claimed |
| EP-0889888-A4 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORP (US) | 2003-01-08 | — | — | EP | claimed |
| US-20020123500-A1 | Use of CSAIDTM compounds as inhibitors of angiogenesis | SMITHKLINE BEECHAM CORPORATION | 2002-09-05 | — | — | US | claimed |
| US-6372741-B1 | ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2002-04-16 | — | — | US | claimed |
| EP-1021173-A1 | USE OF CSAID?TM COMPOUNDS FOR THE MANAGEMENT OF UTERINE CONTRACTIONS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2000-07-26 | — | — | EP | claimed |
| EP-1005343-A1 | USE OF CSAID?TM COMPOUNDS AS INHIBITORS OF ANGIOGENESIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-07 | — | — | EP | claimed |
| EP-1005343-A4 | USE OF CSAID?TM COMPOUNDS AS INHIBITORS OF ANGIOGENESIS | SMITHKLINE BEECHAM CORP (US) | 2000-06-07 | — | — | EP | claimed |
| WO-1999018942-A1 | USE OF CSAIDTM COMPOUNDS FOR THE MANAGEMENT OF UTERINE CONTRACTIONS | IMPERIAL COLLEGE INNOVATIONS LTD. (GB) | 1999-04-22 | — | — | WO | claimed |
| EP-0889888-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-13 | — | — | EP | claimed |
| EP-0831830-A4 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 1998-12-02 | — | — | EP | claimed |
| EP-0831830-A1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1997035856-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-02 | — | — | WO | claimed |
| WO-1997032583-A1 | USE OF CSAIDTM COMPOUNDS AS INHIBITORS OF ANGIOGENESIS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-12 | — | — | WO | claimed |
| US-5658903-A | Imidazole compounds, compositions and use | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-19 | — | — | US | claimed |
| WO-1996040143-A1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-12-19 | — | — | WO | claimed |
| US-4428880-A | Azepino[4,5-d]indole derivatives and preparation thereof | S.A. OMNICHEM (BE) | 1984-01-31 | — | — | US | claimed |
| US-20250354108-A1 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | UNIV DANMARKS TEKNISKE (DK) | 2025-11-20 | — | — | US | disclosed |
| US-4362739-A | Pyrrolo(2,3-d)carbazole derivatives, compositions and use | S.A. OMNICHEM (BE) | 1982-12-07 | — | — | US | disclosed |
| EP-0064317-A2 | Pyrrolo(2,3-d)carbazole derivatives, preparation thereof and their therapeutical use | OMNICHEM Société anonyme (BE) | 1982-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123500-A1 | Use of CSAIDTM compounds as inhibitors of angiogenesis | VEGFA, IL1RN, CXCL12 | HTR2A 2775/4885KDM4E 3822/4885ALDH1A1 939/4885 |
| US-20250354108-A1 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | INMT, KARS1, MIA3 | HTR2A 2339/4885KDM4E 2243/4885ALDH1A1 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.